Search

14 May 2024: Commonalities: Nose bleeds, microchip, tumour exceeding limits. More detailed information will be provided in future regarding these commonalities.

30 Apr 2024: She acknowledged that the group have worked hard to reduce the animal numbers and further more Jax have found that certain microchips are more effective than others; further information in regards

14 May 2024: refinement. • Section 3.8: The committee would be interested to know how often the body temperature was measured by the microchip. •

14 May 2024: There have been 36 SC18’s this month. Repeat concerns included: Compound (AAV, Cytokine, Pharmacokinetics, LPS, Chemo) Weight loss, and Microchip.

14 May 2024: Minutes. four compound related. Five different lumps other than tumours, six microchip incidents, two seizures and two hind limb paralysis.

14 May 2024: Commonalities: 1 Microchip, 1 hind limb paralysis, 16 compound-related (cell solution, MIA toxicity, high IGA), 10 mice found dead, 9 weight loss, 2 irradiation, 2 Leukaemia, 2 G/A IVIS,

17 Jan 2024: In the last month there have been 32 Standard condition 18’s submitted and repeat concerns were microchips, gavage, mis-dose, restraint, weight loss and tumour overgrowth.

23 Jan 2024: There were 36 SC18’s this month Commonalities included nose bleeds, microchips, tumours exceeding limits.

17 Jan 2024: reported that there have been 31 Standard Condition 18’s since the last meeting with repeat issues regarding Weight loss; Microchip bruising/haemorrhage; i/p injection; o/g technique; miss-dose;

17 Jan 2024: Other commonalities are microchip bruising and haemorrhage, nose bleeds, Tamoxifen animals, and metastatic tumour.